Shares of MediciNova (MNOV), a small biotech, rose sharply Monday, but for a reason that may not hold up to scientific scrutiny.
MediciNova announced the early termination of a mid-stage study because of positive results in patients with NASH, or nonalcoholic steatohepatitis, a fatty liver disease. MediciNova shares rose 20 percent to $12.33.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
A cheap way to cut triglycerides is to consume less sugar. Treating the symptoms of a bad diet is not good medicine but slipstreaming the soft drinks industry is probably excellent business